Replies to post #234 on Precision BioSciences Inc (DTIL)

[jondoeuk]

He has now taken up the same position at Tune Therapeutics, which is not far from where this company is located. Matt Kane (another founder of DTIL) is the CEO.

As for antigen downregulation, that is one mechanism of resistance. Antigen loss (up to 30% of B-cell ALL patients who initially respond can relapse with a CD19 negative clone(s)), truncated protein, or downregulation, loss or mutation of CD58 are others https://www.jci.org/articles/view/159402

Long-term (assuming positive clinical data this year), want 19B to displace 2nd/3rd-line auto, but other companies are already working on ways to overcome those and other mechanisms of resistance. So, I think they should be doing the same, including creating an anti-CD19/CD20 CAR https://aacrjournals.org/cancerimmunolres/article/4/6/498/468518/T-Cells-Expressing-CD19-CD20-Bispecific-Chimeric https://ashpublications.org/blood/article/136/Supplement%201/53/470303/CD58-Aberrations-Limit-Durable-Responses-to-CD19 https://www.abstractsonline.com/pp8/#!/10828/presentation/3056